CHMP recommends adding sleep apnea trial data to the EU Mounjaro label
European regulators recommended folding sleep apnea trial results into Mounjaro's existing label instead of creating a separate approved use, a procedural step that still expands what doctors and patients in the EU can read about the drug's effects on obstructive sleep apnea.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on December 12, 2024, for variation II/0027 to the Mounjaro marketing authorization [1]. The change updates sections 4.1, 4.8 and 5.1 of the drug's Summary of Product Characteristics (SmPC) using final results from two Phase 3 trials, listed as IBF-MC-GPI1 and IBF-MC-GPI2 [1]. These studies are described as multicenter, randomized, parallel-arm, double-blind, placebo-controlled trials that tested tirzepatide against placebo in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity [1]. The package leaflet was updated to match [1].
Notably, the filing was classified under category C.I.6.a, which covers "addition of a new therapeutic indication or modification of an approved one" [1]. But rather than creating a standalone EU indication for sleep apnea, the update was folded into the sections that already describe Mounjaro's approved uses, side effects, and pharmacological properties [1]. Section 4.1 covers therapeutic indications, 4.8 covers undesirable effects, and 5.1 covers pharmacodynamic properties [1]. A European Commission decision to formally implement this label change followed on February 14, 2025 [1].
This sleep apnea variation sits within a much longer procedural history for Mounjaro in Europe. Records show tirzepatide's EU label has gone through many changes since its original authorization, including a 2023 extension of indication for chronic weight management based on the SURMOUNT-1 trial [1], and a separate 2026 update tied to the SUMMIT trial in heart failure with preserved ejection fraction and obesity [1]. The sleep apnea update from December 2024 is one part of that broader pattern of label revisions as new trial data become available [1].
The source document is a procedural table from the EMA listing every application, opinion date, and commission decision date affecting Mounjaro's authorization, rather than a narrative press release [1]. It does not include patient-facing details such as specific outcome numbers from the OSA trials, dosing changes, or direct quotes from regulators or the manufacturer [1].
Why it matters for patients
For patients in the European Union, this means that if their doctor prescribes Mounjaro (tirzepatide) and they also have obstructive sleep apnea, the official EU product information now includes data from trials specifically studying that condition [1]. That gives doctors more documented evidence to discuss when weighing the drug's effects for patients who have both obesity and OSA [1].
Because CHMP folded this into existing label sections rather than creating a new indication, the sources do not say whether this changes what Mounjaro is formally indicated to treat in the EU, or whether it affects reimbursement, prescribing rules, or eligibility criteria [1]. It is not yet known from the available records what specific efficacy or safety numbers from the OSA trials were added to the label text [1].
This is an EU regulatory action. The source document does not address whether or how this affects the US label for Zepbound or Mounjaro, both of which are tirzepatide products marketed by Eli Lilly, or whether the FDA has taken or plans a similar step [1]. Readers in the United States should not assume this EU label update applies to their prescribing information without separate confirmation.
What happens next
The European Commission decision implementing this label change took effect February 14, 2025 [1]. The procedural record shows Mounjaro's EU authorization continuing to be amended afterward, including further periodic safety update assessments and manufacturing-related variations through 2025 and into 2026 [1]. A separate, larger label update tied to heart failure trial data (SUMMIT) has an opinion date listed as January 29, 2026, in the same procedural table [1], though the sources do not clarify how that later change relates to the sleep apnea update discussed here.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.